Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.59 |
| ▸ | ACE | P12821 | 10/20 | 0.58 |
| ▸ | MME | P08473 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL199165 | 1.00 | PDPK1 (0.59) | PDPK1ACEMME | |
| SCHEMBL5698838 | 1.00 | PDPK1 (0.59) | PDPK1ACEMME | |
| SCHEMBL30320116 | 1.00 | PDPK1 (0.59) | PDPK1ACEMME | |
| SCHEMBL10907281 | 0.99 | PDPK1 (0.58) | PDPK1ACEMME | |
| SCHEMBL10907286 | 0.99 | PDPK1 (0.58) | PDPK1ACEMME | |
| SCHEMBL7342505 | 0.92 | ACE (0.56) | PDPK1ACEMME | |
| SCHEMBL10596467 | 0.91 | PDPK1 (0.53) | PDPK1ACEMME | |
| SCHEMBL7442610 | 0.90 | PDPK1 (0.52) | PDPK1ACEMME | |
| SCHEMBL9802412 | 0.89 | PDPK1 (0.47) | PDPK1ACEMME | |
| SCHEMBL12893387 | 0.88 | ACE (0.48) | PDPK1ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | claimed |
| EP-1991572-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | claimed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20020183249-A1 | Method of identifying inhibitors of CDC25 | TAYLOR NEIL R (AU) | 2002-12-05 | — | — | US | claimed |
| WO-2002070680-A1 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-12 | — | — | WO | claimed |
| EP-1226237-A2 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-31 | — | — | EP | claimed |
| WO-2001016300-A2 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-08 | — | — | WO | claimed |
| CN-113292495-B | Synthesis method of (S) -amino compound | 迪嘉药业集团有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-113292495-A | Synthesis method of (S) -amino compound | 迪嘉药业集团有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-9447146-B2 | Guanylylcyclase C ligands | THOMAS JEFFERSON UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447146-B2 | Guanylylcyclase C ligands | THOMAS JEFFERSON UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8906844-B2 | Immunomodulatory peptides | BIOGEN IDEC HEMOPHILIA INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-4816466-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-03-28 | — | — | US | disclosed |
| EP-0187037-A2 | Piperidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-07-09 | — | — | EP | disclosed |
| US-4575503-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1986-03-11 | — | — | US | disclosed |
| US-4473575-A | ANGIOTENSIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-09-25 | — | — | US | disclosed |
| US-4410520-A | ANGIOTENSION CONVERTING ENZYME INGIBITOR, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0072352-A1 | Benzazepin-2-ones, process for their preparation, pharmaceutical preparations containing these compounds and the compounds for therapeutical use | CIBA-GEIGY AG (CH) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183249-A1 | Method of identifying inhibitors of CDC25 | CDC25C, CDC25A, CDC25B | PDPK1 931/4885ACE 2236/4885MME 1140/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | PDPK1 4224/4885ACE 1806/4885MME 534/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | PDPK1 4224/4885ACE 1806/4885MME 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.